Min Li1, Limin Zhai, Siming Zeng, Qiliu Peng, Jian Wang, Yan Deng, Li Xie, Yu He, Taijie Li. 1. *PhD †MD Department of Ophthalmology, The People's Hospital of Guangxi Zhuang Autonomous Region, Guangxi, China (ML, SZ); and Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University, Guangxi, China (LZ, QP, JW, YD, LX, YH, TL).
Abstract
PURPOSE: Previous evidence has indicated that the lumican (LUM) gene is a candidate susceptibility gene of high myopia; however, the association between LUM promoter regions rs3759223 polymorphism and high myopia remains controversial and ambiguous. This study performed a meta-analysis to clarify the association between the rs3759223 polymorphism and high myopia risk. METHODS: Eligible studies were identified by comprehensive search of PubMed, EMBASE, Web of Science, and Chinese Biomedical Literature database. The crude odds ratios (ORs) and their corresponding 95% confidence intervals (CIs) were used to estimate the association between the rs3759223 polymorphism and high myopia susceptibility. Meta-regression and subgroup analyses were performed to identify the source of heterogeneity. RESULTS: Finally, six studies including 1238 cases and 1059 healthy controls were included. Meta-analyses showed no association between rs3759223 polymorphism and high myopia susceptibility in all genetic models (CC vs. TT, OR = 1.089; 95% CI, 0.690 to 1.718; CT vs. TT, OR = 0.865; 95% CI, 0.646 to 1.157; CC + CT vs. TT, OR = 1.202; 95% CI, 0.730 to 1.980; CC vs. CT + TT, OR = 0.914; 95% CI, 0.771 to 1.083) and no significance in subgroup analyses according to the definition of high myopia (based on more myopic than -6.00 diopters vs. not based on more myopic than -6.00 diopters). Publication bias was not evident in this study. CONCLUSIONS: This meta-analysis has suggested that there is a lack of association of the rs3759223 polymorphism with high myopia risk. However, further large and well-designed studies with the consideration of LUM gene locus interactions and gene-gene and gene-environment interactions are still required to further evaluate high myopia risk.
PURPOSE: Previous evidence has indicated that the lumican (LUM) gene is a candidate susceptibility gene of high myopia; however, the association between LUM promoter regions rs3759223 polymorphism and high myopia remains controversial and ambiguous. This study performed a meta-analysis to clarify the association between the rs3759223 polymorphism and high myopia risk. METHODS: Eligible studies were identified by comprehensive search of PubMed, EMBASE, Web of Science, and Chinese Biomedical Literature database. The crude odds ratios (ORs) and their corresponding 95% confidence intervals (CIs) were used to estimate the association between the rs3759223 polymorphism and high myopia susceptibility. Meta-regression and subgroup analyses were performed to identify the source of heterogeneity. RESULTS: Finally, six studies including 1238 cases and 1059 healthy controls were included. Meta-analyses showed no association between rs3759223 polymorphism and high myopia susceptibility in all genetic models (CC vs. TT, OR = 1.089; 95% CI, 0.690 to 1.718; CT vs. TT, OR = 0.865; 95% CI, 0.646 to 1.157; CC + CT vs. TT, OR = 1.202; 95% CI, 0.730 to 1.980; CC vs. CT + TT, OR = 0.914; 95% CI, 0.771 to 1.083) and no significance in subgroup analyses according to the definition of high myopia (based on more myopic than -6.00 diopters vs. not based on more myopic than -6.00 diopters). Publication bias was not evident in this study. CONCLUSIONS: This meta-analysis has suggested that there is a lack of association of the rs3759223 polymorphism with high myopia risk. However, further large and well-designed studies with the consideration of LUM gene locus interactions and gene-gene and gene-environment interactions are still required to further evaluate high myopia risk.
Authors: Milly S Tedja; Annechien E G Haarman; Magda A Meester-Smoor; Jaakko Kaprio; David A Mackey; Jeremy A Guggenheim; Christopher J Hammond; Virginie J M Verhoeven; Caroline C W Klaver Journal: Invest Ophthalmol Vis Sci Date: 2019-02-28 Impact factor: 4.799